Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time.
Thirty-three patients with vaginal candidosis were treated with natamycin vaginal tablets for 10 days and their partners were treated double-blind with natamycin cream/placebo cream. Follow-up examinations were carried out one week after the treatment was discontinued and again about one month later. The cure rate in patients having actively treated partners was 94%, not differing significantly from the cure rate of 88% in patients whose partners had been treated with placebo. One month after the treatment there was a high recurrence/re-infection rate, about 30% in both groups. Thus, treating the partners of patients with vaginal candidosis has no influence upon the therapeutic outcome or recurrence rate. The recurrence is presumably due to re-infection from the patient herself.
D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003075:Coitus; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010866:Natamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence
D010866:Natamycin